About: Endothelial Injury and Thrombotic Microangiopathy in COVID-19: Treatment with the Lectin-Pathway Inhibitor Narsoplimab

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Endothelial Injury and Thrombotic Microangiopathy in COVID-19: Treatment with the Lectin-Pathway Inhibitor Narsoplimab Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Endothelial Injury and Thrombotic Microangiopathy in COVID-19: Treatment with the Lectin-Pathway Inhibitor Narsoplimab
Creator	Remuzzi, Giuseppe Fagiuoli, Stefano Frigeni, Marco Gritti, Giuseppe Landi, Francesco Marco, Fabiano Rambaldi, Alessandro Binda, Francesca Borleri, Gianmaria Demopulos, Gregory Gianatti, Andrea Lorini, Luca Micò, Maria Pavoni, Chiara Salvi, Anna Sonzogni, Aurelio Whitaker, Steve Marco, Di
source	Elsevier; PMC
abstract	In COVID-19, acute respiratory distress syndrome (ARDS) and thrombotic events are frequent, life-threatening complications. Autopsies commonly show arterial thrombosis and severe endothelial damage. Endothelial damage, which can play an early and central pathogenic role in ARDS and thrombosis, activates the lectin pathway of complement. Mannan-binding lectin-associated serine protease-2 (MASP-2), the lectin pathway’s effector enzyme, binds the nucleocapsid protein of severe acute respiratory syndrome-associated coronavirus-2 (SARS-CoV-2), resulting in complement activation and lung injury. Narsoplimab, a fully human immunoglobulin gamma 4 (IgG4) monoclonal antibody against MASP-2, inhibits lectin pathway activation and has anticoagulant effects. In this study, the first time a lectin-pathway inhibitor was used to treat COVID-19, six COVID-19 patients with ARDS requiring continuous positive airway pressure (CPAP) or intubation received narsoplimab under compassionate use. At baseline and during treatment, circulating endothelial cell (CEC) counts and serum levels of interleukin-6 (IL-6), interleukin-8 (IL-8), C-reactive protein (CRP) and lactate dehydrogenase (LDH) were assessed. Narsoplimab treatment was associated with rapid and sustained reduction of CEC and concurrent reduction of serum IL-6, IL-8, CRP and LDH. Narsoplimab was well tolerated; no adverse drug reactions were reported. Two control groups were used for retrospective comparison, both showing significantly higher mortality than the narsoplimab-treated group. All narsoplimab-treated patients recovered and survived. Narsoplimab may be an effective treatment for COVID-19 by reducing COVID-19-related endothelial cell damage and the resultant inflammation and thrombotic risk.
has issue date	2020-08-09(xsd:dateTime)
bibo:doi	10.1016/j.imbio.2020.152001
has license	no-cc
sha1sum (hex)	384cf0c563bd9f1e6f85b9f92f2e481b6a5b82fc
schema:url	https://doi.org/10.1016/j.imbio.2020.152001
resource representing a document's title	Endothelial Injury and Thrombotic Microangiopathy in COVID-19: Treatment with the Lectin-Pathway Inhibitor Narsoplimab
has PubMed Central identifier	PMC7415163
schema:publication	Immunobiology
resource representing a document's body	covid:384cf0c563bd9f1e6f85b9f92f2e481b6a5b82fc#body_text
is schema:about of	covid:arg/384cf0c563bd9f1e6f85b9f92f2e481b6a5b82fc named entity 'Lectin' named entity 'Thrombotic Microangiopathy' named entity 'serum' named entity 'COVID' named entity 'endothelial' named entity 'anticoagulant therapy' named entity 'Lectin pathway' named entity 'Complement activation' named entity 'pneumonia' named entity 'microorganisms' named entity 'adaptive immune response' named entity 'immunoglobulin' named entity 'lectin pathway' named entity 'HSCT' named entity 'non-parametric' named entity 'mechanism of action' named entity 'complement' named entity 'antiviral therapy' named entity 'C5b' named entity 'body mass index' named entity 'morphology' named entity 'CD45' named entity 'enzyme' named entity 'interleukin-1β' named entity 'SARS-CoV-2' named entity 'Omeros' named entity 'radiographic' named entity 'non-parametric' named entity 'endothelial' named entity 'Germany' named entity 'complement activation' named entity 'LDH' named entity 'exudative' named entity 'serine protease' named entity 'complement factor' named entity 'Enoxaparin' named entity 'complement factor' named entity 'fibrin' named entity 'anti-inflammatory' named entity 'mechanism of action' named entity 'interleukin-8' named entity 'protein' named entity 'SARS-CoV-2' named entity 'microvascular injury' named entity 'complement factors' named entity 'Thrombosis' named entity 'MASP-2' named entity 'lectin pathway' named entity 'Leica' named entity 'Omeros' named entity 'COVID' named entity 'LDH' named entity 'MASP-2' named entity 'darunavir' named entity 'prothrombin' named entity 'thromboses' named entity 'IL-6' named entity 'COVID' named entity 'lectin pathway' named entity 'C3a' named entity 'DAMPs' named entity 'control groups' named entity 'COVID-19' named entity 'fibrin' named entity 'thrombotic microangiopathy'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software